APL-1702 Photodynamic Therapy in Patients With High-Risk HPV-Positive Cervical Intraepithelial Neoplasia Grade II/III (CIN2/3) (AEGIS)

November 17, 2026 updated by: Yu Zhang, Xiangya Hospital of Central South University

An Exploratory Clinical Study of APL-1702 (Drug-Device Combination) Photodynamic Therapy in Patients With High-Risk HPV-Positive Cervical Intraepithelial Neoplasia Grade 2 or 3 (CIN2/3)

This investigator-initiated, open-label, exploratory study evaluates the safety and preliminary efficacy of APL-1702 photodynamic therapy in participants with high-risk human papillomavirus (hrHPV)-positive cervical intraepithelial neoplasia grade 2 (CIN2) or grade 3 (CIN3). Part 1 enrolls adults with CIN2 into six treatment-regimen groups to identify a preferred regimen, primarily on the basis of histological regression at Week 24 after the first treatment. Part 2 enrolls adults aged 18 to 45 years with hrHPV-positive CIN3 and evaluates three treatments administered at Day 0, Month 1, and Month 3. Participants are assessed for histological regression, hrHPV clearance, and safety.

Study Overview

Study Type

Interventional

Enrollment (Estimated)

159

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Hunan
      • Changsha, Hunan, China, 410008
        • Recruiting
        • Xiangya Hospital of Central South University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  1. Voluntary participation in this study, understanding of the study procedures, and ability to provide written informed consent;
  2. Part 1 Age ≥18 years; Part 2 Age≥18 years and≤45 years
  3. CIN histology: Part 1, hrHPV-positive and histologically confirmed CIN2 within 3 months before the first treatment; Part 2, hrHPV-positive and histologically confirmed CIN3 within 3 months before the first treatment, with the lesion involving 50% or less of the cervical area. Histological eligibility is confirmed by the central laboratory.
  4. Adequate colposcopic examination, with the entire cervical transformation zone and squamocolumnar junction visible and the entire lesion margin visible.
  5. A strong desire to preserve cervical structure and/or function, and the investigator considers non-surgical treatment acceptable.
  6. The investigator considers the cervical size suitable for placement of the APL-1702 device
  7. Negative pregnancy test; no pregnancy planned from study initiation until 3 months after the last treatment or 24 weeks after the first treatment, whichever is later. Participants must have abstained from sexual activity or used effective contraception from the end of the last menstrual period to study entry and must agree to use condoms during the protocol-defined contraceptive period.

Exclusion Criteria:

  1. Cervical adenocarcinoma in situ (AIS), other glandular epithelial lesions, invasive cervical cancer, or suspected malignant lesions.
  2. Lesions extending to the vaginal wall, endocervical canal, vaginal fornix, or vulvar region.
  3. Previous physical or surgical treatment of the cervix resulting in incomplete cervical structure (for example, cold knife conization), or physical or surgical treatment for CIN2 or CIN3 after the current histopathological diagnosis.
  4. The first study treatment occurs within 7 half-lives after the last dose of an antiviral medication.
  5. History of toxic shock syndrome.
  6. Severe pelvic inflammatory disease, severe cervicitis, or other serious gynecological infections identified by colposcopy or clinical examination.
  7. The investigator considers that vaginal bleeding during treatment may affect treatment efficacy.
  8. Administration of any inactivated vaccine within 2 weeks before study treatment or any live vaccine within 4 weeks before study treatment.
  9. Unresolved severe cardiovascular, neurological, psychiatric, endocrine, or hematologic diseases; known severe immunodeficiency; need for long-term glucocorticoids or immunosuppressive therapy; or a history of malignancy within 5 years.
  10. Clinically significant immunosuppression, confirmed autoimmune disease, or primary immunodeficiency.
  11. Known or screening-detected active sexually transmitted diseases (STDs), including but not limited to HIV infection, syphilis, or genital herpes, unless adequately treated with negative results before study treatment.
  12. Presence of a cardiac pacemaker.
  13. Suspected or known porphyria, or known allergy to the study drug or chemically related compounds.
  14. Allergy to silicone.
  15. Pregnant or breastfeeding.
  16. Childbirth or miscarriage within 6 weeks before enrollment.
  17. Participation in another clinical trial within 30 days before study treatment.
  18. Poor compliance or investigator's judgment that the subject is unsuitable for participation.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Sequential Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Part 1 - Q3W x 3

Adults with hrHPV-positive CIN2 receive APL-1702 once every 3 weeks for a total of 3 treatments.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q3W x 3.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q3W x 6.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q2W x 3.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q2W x 6.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q1W x 3.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q1W x 6.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Day 0, Month 1, and Month 3 (3 treatments total).

Experimental: Part 1 - Q3W x 6

Adults with hrHPV-positive CIN2 receive APL-1702 once every 3 weeks for a total of 6 treatments.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q3W x 3.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q3W x 6.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q2W x 3.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q2W x 6.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q1W x 3.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q1W x 6.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Day 0, Month 1, and Month 3 (3 treatments total).

Experimental: Part 1 - Q2W x 3

Adults with hrHPV-positive CIN2 receive APL-1702 once every 2 weeks for a total of 3 treatments.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q3W x 3.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q3W x 6.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q2W x 3.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q2W x 6.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q1W x 3.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q1W x 6.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Day 0, Month 1, and Month 3 (3 treatments total).

Experimental: Part 1 - Q2W x 6

Adults with hrHPV-positive CIN2 receive APL-1702 once every 2 weeks for a total of 6 treatments.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q3W x 3.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q3W x 6.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q2W x 3.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q2W x 6.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q1W x 3.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q1W x 6.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Day 0, Month 1, and Month 3 (3 treatments total).

Experimental: Part 1 - Q1W x 3

Adults with hrHPV-positive CIN2 receive APL-1702 once weekly for a total of 3 treatments.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q3W x 3.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q3W x 6.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q2W x 3.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q2W x 6.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q1W x 3.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q1W x 6.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Day 0, Month 1, and Month 3 (3 treatments total).

Experimental: Part 1 - Q1W x 6

Adults with hrHPV-positive CIN2 receive APL-1702 once weekly for a total of 6 treatments.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q3W x 3.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q3W x 6.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q2W x 3.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q2W x 6.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q1W x 3.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q1W x 6.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Day 0, Month 1, and Month 3 (3 treatments total).

Experimental: Part 2 - Month 0/1/3

Adults aged 18 to 45 years with hrHPV-positive CIN3 receive a total of three APL-1702 treatments.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q3W x 3.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q3W x 6.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q2W x 3.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q2W x 6.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q1W x 3.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q1W x 6.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Day 0, Month 1, and Month 3 (3 treatments total).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Part 1: Histological regression rate at Week 24 after the first treatment
Time Frame: Week 24 after the first treatment

Proportion of Part 1 participants whose post-treatment cervical histopathology is normal, CIN1, or inflammatory changes only, based on central laboratory evaluation of colposcopy-directed cervical biopsy specimens.

Week 24 after the first treatment
Part 2: Histological regression rate at Week 24 after the first treatment
Time Frame: Week 24 after the first treatment

Proportion of Part 2 participants whose post-treatment cervical histopathology is normal, CIN1, or inflammatory changes only, based on central laboratory evaluation of colposcopy-directed cervical biopsy specimens.

Week 24 after the first treatment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Part 1 hrHPV clearance rate
Time Frame: 28 days after the final treatment course and Week 24 after the first treatment

Proportion of Part 1 participants in whom all hrHPV genotype(s) detected at baseline are undetectable after treatment.

28 days after the final treatment course and Week 24 after the first treatment
Part 1 incidence and characteristics of adverse events and serious adverse events
Time Frame: From informed consent through Week 96 after the first treatment

Type, incidence, severity, duration, outcome, and relationship to the study product of adverse events and serious adverse events.

From informed consent through Week 96 after the first treatment
Part 1 long-term hrHPV clearance rate
Time Frame: Weeks 36, 60, and 96 after the first treatment

Proportion of Part 1 participants in whom all hrHPV genotype(s) detected at baseline are undetectable after treatment.

Weeks 36, 60, and 96 after the first treatment
Part 1 long-term histological regression rate
Time Frame: Weeks 36, 60, and 96 after the first treatment

Proportion of Part 1 participants whose post-treatment cervical histopathology is normal, CIN1, or inflammatory changes only.

Weeks 36, 60, and 96 after the first treatment
Part 2 hrHPV clearance rate
Time Frame: Week 24 after the first treatment

Proportion of Part 2 participants in whom all hrHPV genotype(s) detected at baseline are undetectable after treatment.

Week 24 after the first treatment
Part 2 incidence and characteristics of adverse events and serious adverse events
Time Frame: From informed consent through Week 48 after the first treatment

Type, incidence, severity, duration, outcome, and relationship to the study product of adverse events and serious adverse events.

From informed consent through Week 48 after the first treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 26, 2025

Primary Completion (Estimated)

January 1, 2028

Study Completion (Estimated)

July 1, 2029

Study Registration Dates

First Submitted

November 11, 2026

First Submitted That Met QC Criteria

November 17, 2026

First Posted (Actual)

November 18, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 17, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe